Bencheqroun, 52 patient nigella sativa early treatment RCT: 9% faster improvement [p=0.78] and 43% improved viral clearance [p=0.31] https://c19p.org/bencheqroun
copied to clipboard
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of ThymoQuinone Formula (TQF) for Treating Outpatient SARS-CoV-2
et al., Pathogens, doi:10.3390/pathogens11050551
52 patient RCT in the USA with nigella sativa component thymoquinone, showing improved recovery with treatment. There was a significantly faster decline in the total symptom burden, and a significant increase in CD8+ and helper CD4+ central memory T lymphocytes. The treatment group contained 5 more vaccinated patients and 7 more overweight patients. Authors also present in vitro results showing an inhibitory effect with five SARS-CoV-2 variants including omicron.
|
risk of hospitalization, 69.3% lower, RR 0.31, p = 0.44, treatment 0 of 29 (0.0%), control 1 of 23 (4.3%), NNT 23, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
|
time to sustained clinical response, 9.1% lower, HR 0.91, p = 0.78, treatment 28, control 23, inverted to make RR<1 favor treatment, Kaplan–Meier.
|
|
time to sustained clinical response, 35.5% lower, HR 0.65, p = 0.25, treatment 28, control 23, inverted to make RR<1 favor treatment, Kaplan–Meier, high-risk patients.
|
|
risk of no viral clearance, 43.5% lower, RR 0.57, p = 0.31, treatment 5 of 21 (23.8%), control 8 of 19 (42.1%), NNT 5.5, day 14.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Bencheqroun et al., 7 May 2022, Double Blind Randomized Controlled Trial, placebo-controlled, USA, peer-reviewed, mean age 45.0, 25 authors, study period 27 May, 2021 - 27 September, 2021.
Contact:
h.bencheqroun@respireresearch.com (corresponding author), r.fortunet@respireresearch.com, yasirahmed.med@gmail.com, cbarrera@ummc.care, mariya@ummc.care, mehmet.kocaktas@gmail.com, evilla@moraleshealthcare.com, emmanueli@tranquilconsulting.com, deborahb@tranquilconsulting.com, chineduo@tranquilconsulting.com, olaa@tranquilconsulting.com, karim@tranquilconsulting.com, spondell@ibtsolutions.us, amr.mohamed@uhhospitals.org, yimohamed@mdanderson.org, bgok@mdanderson.org, mkaseb1@gmail.com, okasseb@hotmail.com, mgocio@novatekpharmaceuticals.com, pt22064@comcast.net, danli@mdanderson.org, qma@mdanderson.org, jimmy_lu@codexbio.com, abdu94@yahoo.com, akaseb@mdanderson.org.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.